ACCORDING TO EMA DATA
On 08 September 2021, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency published an update of safety information on COVID-19 vaccines, based on the assessment of safety reports received from around the world.
All vaccines against COVID-19
Multisystem inflammatory syndrome (MIS)
Assessment ongoing
Several cases of MIS were reported after administration of Comirnaty and another COVID-19 vaccine in adults, both within the EU and outside it. The reported cases occurred after vaccination but are not necessarily related to the vaccine or caused by it.
MIS is a serious inflammatory condition that affects many parts of the body. Symptoms may include fatigue, persistent fever, diarrhea, vomiting, stomach and chest pain, headache and difficulty breathing.
MIS is rare. The incidence before the COVID-19 pandemic was (according to data from 5 European countries) between 2 and 6 cases per 100 000 per year in children and adolescents under 20 years of age and fewer than 2 cases per 100 000 per year in adults aged 20 years and older.
There are also reports of the development of MIS following COVID-19 infection (however, in the history of one vaccinated patient with MIS from Denmark, COVID-19 infection was not established).
As of August 19, 2021, one case of MIS-C in a child after vaccination with Comirnaty had been registered in EudraVigilance. No cases of MIS-C in children were recorded with Spikevax (Moderna), Janssen, and Vaxzevria.
PRAC urges all healthcare professionals to report cases of MZS and other adverse events following immunization.
Vaxzevria
Guillain-Barré syndrome
Update of the instructions for medical use
Information on Guillain-Barré syndrome (GBS) was added to the section “Special warnings and precautions for use” of the instructions for medical use following the PRAC decision in July 2021.
Based on the evaluation of updated data and taking into account the opinion of neurology experts, PRAC concluded that a causal relationship between the use of the vaccine and the development of GBS is at least possible; therefore, GBS with the frequency “Very rare” (in fewer than 1 person out of 10000 vaccinated) must be added to the “Adverse reactions” section of the instructions for medical use.
Thrombosis with thrombocytopenia
Update of the instructions for medical use
In May 2021, the instructions for medical use were updated to include information on thromboses in combination with thrombocytopenia.
In September 2021, the PRAC decided to further update the instructions for medical use by removing the current information that reported cases of thrombosis in combination with thrombocytopenia occurred mainly in women under 60 years of age.
Spikevax (Moderna)
Delayed injection site reactions
Assessment ongoing
The PRAC requested additional data from the registration certificate holder for the evaluation, namely: time to onset of the reaction, duration, and severity of manifestations. The instructions for medical use will be updated subsequently.
Diarrhea
Assessment ongoing
The PRAC recommended that the registration certificate holder add the clinical manifestation “Diarrhea” to the “Adverse reactions” section of the instructions for medical use with the frequency determined from the latest clinical trial data.
Janssen
Venous thromboembolism (VTE)
Assessment ongoing
VTE was included in the risk management plan as a safety concern requiring further study (in the first clinical studies, a greater number of VTE cases was observed in the vaccinated group compared with the placebo group).
PRAC will evaluate additional data obtained in two large clinical studies in order to further assess whether VTE may be associated with the vaccine.
Other events: Lymphadenopathy, paresthesia, hypoesthesia, tinnitus, diarrhea and vomiting
PRAC has completed its assessment and recommended making the following changes to the “Adverse reactions” section of the instructions for medical use:
- lymphadenopathy with the frequency “Rare” (in fewer than 1 in 1000 vaccinated persons);
- paresthesia with the frequency “Uncommon” (in fewer than 1 out of 100 vaccinated persons), and hypoesthesia – “Rare” (i.e., occurring in fewer than 1 out of 1000 vaccinated persons);
- tinnitus with the frequency “Rare” (i.e., occurs in fewer than 1 in 1000 vaccinated persons)..
- diarrhea with the frequency “Uncommon” (i.e., occurring in fewer than 1 in 100 vaccinated individuals), and vomiting – “Rare” (i.e., occurring in fewer than 1 in 1000 vaccinated individuals).
The original text of the publication is available at the following links: